Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott E Plevy

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Gastroenterology|December 26, 2012
Carbon monoxide and heme oxygenase-1 prevent intestinal inflammation in mice by promoting bacterial clearanceJoseph C Onyiah, Shehzad Z Sheikh, Nitsan Maharshak, et al.
Inflammatory Bowel Diseases|January 5, 2013
Lectin-based immunoassay for aberrant IgG glycosylation as the biomarker for Crohn's diseaseShinichiro Shinzaki, Eri Kuroki, Hideki Iijima, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 21, 2014
NFIL3-deficient mice develop microbiota-dependent, IL-12/23-driven spontaneous colitisTaku Kobayashi, Erin C Steinbach, Steven M Russo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 18, 2014
Innate PI3K p110δ regulates Th1/Th17 development and microbiota-dependent colitisErin C Steinbach, Taku Kobayashi, Steven M Russo, et al.
Nature Immunology|March 14, 2017
NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growthLiang Chen, Justin E Wilson, Mark J Koenigsknecht, et al.
Nature Immunology|October 19, 2017
Corrigendum: NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growthLiang Chen, Justin E Wilson, Mark J Koenigsknecht, et al.
Inflammatory Bowel Diseases|May 17, 2019
Challenges in IBD Research: Environmental TriggersShuk-Mei Ho, James D Lewis, Emeran A Mayer, et al.
Inflammatory Bowel Diseases|August 29, 2009
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitisDaniel C Baumgart, Stephan R Targan, Axel U Dignass, et al.
Nature Medicine|April 4, 2017
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel diseaseNathaniel R West, Ahmed N Hegazy, Benjamin M J Owens, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Gastroenterology|December 26, 2012
Carbon monoxide and heme oxygenase-1 prevent intestinal inflammation in mice by promoting bacterial clearanceJoseph C Onyiah, Shehzad Z Sheikh, Nitsan Maharshak, et al.
Inflammatory Bowel Diseases|January 5, 2013
Lectin-based immunoassay for aberrant IgG glycosylation as the biomarker for Crohn's diseaseShinichiro Shinzaki, Eri Kuroki, Hideki Iijima, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 21, 2014
NFIL3-deficient mice develop microbiota-dependent, IL-12/23-driven spontaneous colitisTaku Kobayashi, Erin C Steinbach, Steven M Russo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 18, 2014
Innate PI3K p110δ regulates Th1/Th17 development and microbiota-dependent colitisErin C Steinbach, Taku Kobayashi, Steven M Russo, et al.
Nature Immunology|March 14, 2017
NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growthLiang Chen, Justin E Wilson, Mark J Koenigsknecht, et al.
Nature Immunology|October 19, 2017
Corrigendum: NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growthLiang Chen, Justin E Wilson, Mark J Koenigsknecht, et al.
Inflammatory Bowel Diseases|May 17, 2019
Challenges in IBD Research: Environmental TriggersShuk-Mei Ho, James D Lewis, Emeran A Mayer, et al.
Inflammatory Bowel Diseases|August 29, 2009
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitisDaniel C Baumgart, Stephan R Targan, Axel U Dignass, et al.
Nature Medicine|April 4, 2017
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel diseaseNathaniel R West, Ahmed N Hegazy, Benjamin M J Owens, et al.
Pageof 5